Results 31 to 40 of about 166,449,558 (233)
Giant cell tumor of bone: risk factors for recurrence [PDF]
, 2011 Many surgeons treat giant cell tumor of bone (GCT) with intralesional curettage. Wide resection is reserved for extensive bone destruction where joint preservation is impossible or when expendable sites (eg, fibular head) are affected.
Franklin H. Sim +9 more
core +2 more sources
Palatal Swelling: A Diagnostic Enigma
Case Reports in Dentistry, 2016 Giant cell tumor (GCT) of bone is a giant-cell-rich bony lesion associated with abundant multinucleated osteoclast-type giant cells. It is a primary neoplasm of bone with characteristic clinical, radiological, and pathological features.
Ramalingam Suganya +4 more
doaj +1 more source
An intraosseous giant cell granuloma: An uncommon presentation
Journal of Pharmacy and Bioallied Sciences, 2021 The giant cell granuloma is an identical reactive lesion which is mostly progressive in nature. The clinical behavior of these lesions varies from indolent to aggressive variant.
V Ravi Pavan +3 more
doaj +1 more source
Oral giant cell tumor or giant cell granuloma: How to know?
Heliyon, 2023 Introduction: The distinction between giant cell tumors and giant cell granulomas is challenging, as both entities have overlapping diagnostic criteria, especially in oral locations.
E. Hoarau +6 more
doaj +1 more source
Giant-cell tumors of bone in South India [PDF]
, 1974 Giant-cell tumors of bone are rare or uncommon. Dodge reported that giant-cell tumor is rare in Ugandan Africans, but Hadley and associates and Rockwell and Small noted that giant-cell tumor of bone is comparatively common in South India.
Rajakumari, K. +2 more
core +2 more sources
Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience
Diagnostic Pathology, 2012 Background Multinucleated giant cell-containing tumors and pseudotumors of bone represent a heterogeneous group of benign and malignant lesions. Differential diagnosis can be challenging, particularly in instances of limited sampling. The purpose of this
Hammas Nawal +6 more
doaj +1 more source
Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions
Türk Patoloji Dergisi, 2022 Objective: To assess P63 expression in giant cell-containing lesions of the bone (GCLB) and to determine its utility in differentiating giant cell tumor of the bone (GCTB) from other GCLBs.
Monalisa HUI +5 more
doaj +1 more source
Clinical periodontal diagnosis
Periodontology 2000, EarlyView., 2023 Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi +5 more
wiley +1 more source
Journal of Bone Oncology, 2019 Background: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven. Objectives: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with ...
Shenglong Li, Peng Chen, Qiankun Yang
doaj +1 more source
Advanced Materials for Biologics Delivery to Brain Tumors
Advanced Materials, EarlyView.Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source